Skip to content

Author

Xiao-Hui Zhang

7 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

CD34+-selected stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation: a large cohort study focusing on haploidentical transplantation.

CD34+-selected stem cell boost is safe and highly effective for refractory PGF after allo-HSCT, including in haploidentical recipients and those who have failed TPO-RAs.

Y. He, Lin-Wei Shi, R. Ma et al. · 0 citations
Open access Oct 2026

Distinct cellular dynamics following CD19 and CD7 CAR-T therapies revealed by high-dimensional CyTOF analysis and impact on clinical outcomes

Compared with CD19 CAR-T therapy, CD7 CAR-T therapy was characterized by reduced CD8+ CAR-T persistence, early exhaustion, and delayed immune reconstitution, correlating with increased infections and higher non-relapse mortality.

Zhi-Peng Zhou, Yi-Yang Ding, Zhuo-Jun Liu et al. · 0 citations
Open access Sep 2026

Haploidentical HSCT vs immunosuppressive therapy for severe aplastic anemia in patients aged 40-65 years: a retrospective comparative study

Abstract Severe aplastic anemia (SAA) is a life-threatening hematological disorder, and the optimal treatment for patients aged ≥40 years remains controversial. This retrospective study aims to conduct a comparative analysis of the efficacy of immunosuppressive therapy (IST) versus haploidentical hematopoietic stem cel...

Sheng-Quan Gao, Jin-Song Jia, Xiao-Jun Huang et al. · 0 citations
Review Open access Sep 2026

Age‐Stratified Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndromes: A Comprehensive Review

Myelodysplastic syndromes (MDS) are clonal disorders with high risk of progression to acute myeloid leukemia (AML). Allogeneic haematopoietic stem cell transplantation (allo‐HSCT), including haploidentical HSCT (haplo‐HSCT), is the only curative option. Age‐stratified selection of conditioning regimens based on organ r...

Ning Wu, Meng Lv, Xiao-Dong Mo et al. · 0 citations
Oct 2026

Rapid Manufactured CAR-T Cells enriched for CD45RA-negative T cells Exhibit Superior Persistence Compared to Conventional CAR-T Therapy.

CD19 CAR-T has achieved high remission rates in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, rapid generation with durable in vivo persistence remains a major challenge. CD45RA-negative T cells exhibit sustained antileukemic activity and preserved immune memory. Here, we developed a rapid p...

Xu-Ying Pei, Meng Lv, Xiao-Zheng Zhao et al. · 0 citations
Open access Sep 2026

Letermovir for cytomegalovirus prophylaxis after allogeneic hematopoietic stem cell transplantation in acute leukemia patients: results of the LETreal study

Objective Cytomegalovirus (CMV) infection can cause severe morbidity and mortality in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Letermovir is recommended as CMV prophylaxis for allo-HSCT recipients. This study aimed to further confirm the efficacy of letermovir prophylaxis in d...

Yi Xia, Qi Wen, Jing Liu et al. · 0 citations
Sep 2026

Ectopic EBV Infection in T Cells Identifies Reduced Therapeutic Responsiveness and Immune Dysfunction After Allogeneic Hematopoietic Stem Cell Transplantation.

OBJECTIVES EBV reactivation after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is typically monitored by plasma viral load, but this fails to capture cellular reservoirs. Lineage-specific testing, though usually performed in high-risk patients, may identify biologically distinct disease states. We aim...

Zhi-Fan Zhao, Zhuo-Jun Liu, Qiang Huang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.